Mountain Crest V
AUM Biosciences Pte. Ltd., a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, and Mountain Crest Acquisition Corp. V (Nasdaq: MCAG), a publicly-traded special purpose acquisition company, whose management team has an impressive pedigree of successful SPAC transactions, announced that, on October 20 of 2022, they have entered into a definitive business combination agreement.